Home › Research › Brain scans and imaging
[18F] RO948 Tau PET imaging and plasma biomarkers in PART and LATE patients compared with sporadic Alzheimer's Disease
Agneta K. Nordberg, Marco Brady Bucci, Mariola Zapater‐Fajarí, Konstantinos Chiotis, Anders E. Wall, Jonas Eriksson, Gunnar Antoni, Ilaria Pola et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract Background Although the diagnosis of Alzheimer´s disease (AD) dominates in the tertiary memory clinic setting, there are also patients which show no sign for presence of amyloid in brain when assessed for CSF biomarkers after lumbar puncture (LP) or amyloid PET. Since these amyloid negative (A‐) patients can clinically mimic symptomatic AD patients, it is important to obtain further insight into the in vivo pathology of these patients. This study therefore aimed to perform tau PET imaging with the tracer [18F]RO948 and measure plasma biomarkers in patients clinically diagnosed as primary age‐related tauopathy (PART) and limbic dominant TDP‐43 age‐related encephalopathy (LATE) at the clinic for cognitive disorders at Karolinska University Hospital. Method Four patients diagnosed with PART (mean age 76 years) and four with LATE (mean age 79 years) were included in the study. Clinical characteristics and biomarkers are reported in Table 1. The ATN classification for PART patients was A‐T+N+ and for LATE patients A‐T‐N+. On the same day, all participants underwent [18F]RO948 tau PET and MRI scans, and blood sampling for plasma biomarker analysis using the NuLISAseq (Alamarbio) CNS panel. The obtained data was compared with 27 amyloid positive MCI and AD patients from Karolinska as well as 10 cognitive healthy controls. Result Low uptake of [18F]RO948 was observed in PART and LATE brains compared to MCI A+ as shown in Figure 1, including also Radar plots of different brain regions. Box plot data (Figure 2) showed low [18F]RO948 regional uptake except for a higher uptake ( p <0.05) in the putamen in PART and LATE compared to controls. Higher plasma levels of ptau217, ptau181, ptau231 were observed in PART patients ( p <0.05) but not in LATE compared to cognitively healthy controls. Plasma ptau217 levels were however higher in LOAD ( p <0.05) compared to PART. Higher plasma Aß42 values were observed both in LATE and PART compared to LOAD. Conclusion PART and LATE patients exhibit Tau PET uptake similar to that of controls, except in the putamen. Additionally, PART patients show elevated plasma levels of p ‐tau 217, p ‐tau 181, and p ‐tau 231, whereas LATE patients do not.
What this study adds
Evidence grade: Low
In four PART and four LATE patients, [18F]RO948 tau-PET showed low uptake compared with amyloid-positive MCI patients, with higher putamen uptake than controls. The very small sample size makes this preliminary, and it addresses diagnosis and in vivo pathology rather than treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nordberg, A. K., Bucci, M. B., Zapater‐Fajarí, M., Chiotis, K., Wall, A. E., Eriksson, J., et al. (2025). [18F] RO948 Tau PET imaging and plasma biomarkers in PART and LATE patients compared with sporadic Alzheimer's Disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_107395
Vancouver
Nordberg AK, Bucci MB, Zapater‐Fajarí M, Chiotis K, Wall AE, Eriksson J, et al. [18F] RO948 Tau PET imaging and plasma biomarkers in PART and LATE patients compared with sporadic Alzheimer's Disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_107395.
BibTeX
@article{nordberg2025-1419fb90,
author = {Nordberg, Agneta K. and Bucci, Marco Brady and Zapater‐Fajarí, Mariola and Chiotis, Konstantinos and Wall, Anders E. and Eriksson, Jonas and Antoni, Gunnar and Pola, Ilaria and others},
title = {{[18F] RO948 Tau PET imaging and plasma biomarkers in PART and LATE patients compared with sporadic Alzheimer's Disease}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_107395},
url = {https://doi.org/10.1002/alz70856_107395}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The obtained data was compared with 27 amyloid positive MCI and AD patients from Karolinska as well as 10 cognitive healthy controls.
- Result Low uptake of [18F]RO948 was observed in PART and LATE brains compared to MCI A+ as shown in Figure 1, including also Radar plots of different brain regions.
- Box plot data (Figure 2) showed low [18F]RO948 regional uptake except for a higher uptake ( p <0.05) in the putamen in PART and LATE compared to controls.
- Higher plasma levels of ptau217, ptau181, ptau231 were observed in PART patients ( p <0.05) but not in LATE compared to cognitively healthy controls.
- Plasma ptau217 levels were however higher in LOAD ( p <0.05) compared to PART.
Why it matters
In four PART and four LATE patients, [18F]RO948 tau-PET showed low uptake compared with amyloid-positive MCI patients, with higher putamen uptake than controls. The very small sample size makes this preliminary, and it addresses diagnosis and in vivo pathology rather than treatment or cure.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Nenad Bogdanović: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 14 institution(s) in 4 countries |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Brain scans and imaging from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.